New Blood Test Shows Promise in Early Glioblastoma Detection

Researchers in Great Britain and Denmark have developed a blood test that, in a new study, can distinguish patients with glioblastoma from healthy control subjects with around 90 percent accuracy. The findings offer a potential new tool for earlier diagnosis of the aggressive brain cancer, though experts caution it remains in the research phase.

Glioblastoma: A Challenging Diagnosis

Glioblastoma is the most common and aggressive type of primary brain cancer in adults. It is characterized by rapid growth and resistance to treatment, leading to a poor prognosis. Current diagnostic methods rely heavily on MRI examinations and tissue samples obtained through biopsy or surgery.

How the New Blood Test Works

The study, published in Neuro-Oncology Advances on February 5th, identified two proteins in the blood that may serve as biomarkers for glioblastoma. Researchers analyzed blood and tissue samples from patients with the cancer and found the test accurately identified 90% of patients with primary glioblastoma when compared to healthy individuals.

The test too showed promise in monitoring disease progression and treatment response, correctly identifying 82% of patients with recurrent glioblastoma.

Danish Collaboration and AI Integration

The research involved collaboration between the University of Manchester and Danish institutions, utilizing samples collected at Rigshospitalet in Copenhagen between 2010 and 2020. Researchers employed artificial intelligence to analyze large datasets, a departure from previous research that focused primarily on genetic material (DNA).

Potential Impact on Diagnosis and Treatment

Professor and senior physician Petter Brandal at Radiumhospitalet emphasizes the potential benefits of early diagnosis: “Early diagnosis gives most people a better chance of removing as much of the tumor as possible during surgery.” However, he also notes the ongoing challenges in treating glioblastoma and the need for more effective therapies.

Researchers envision the blood test eventually supplementing, rather than replacing, existing diagnostic methods like MRI. The long-term goal is to use the test to help doctors determine which patients should be referred for immediate MRI scans, potentially accelerating diagnosis and treatment.

Further Research Needed

The researchers acknowledge that further studies are necessary to refine the test’s accuracy and broaden its applicability. Current research has primarily focused on distinguishing glioblastoma from healthy controls, and more operate is needed to differentiate it from other brain tumors and conditions with similar symptoms. Ongoing studies are also exploring new treatments for glioblastoma, including immunotherapy and targeted drug therapies.